Ishihara M, Fedarko N S, Conrad H E
J Biol Chem. 1987 Apr 5;262(10):4708-16.
A rat hepatocyte cell line was cultured in Higuchi's medium with fetal calf serum and insulin and labeled with 35SO2/4-. The cells were treated with a number of ligands to displace the heparan 35SO4 proteoglycan (HSPG) from the pericellular matrix. Maximum release was obtained with D-mannose-6-PO4 (50 mM), D-glucose-6-PO4 (50 mM), myo-inositol-2-PO4 (2-5 mM), myo-inositol hexaphosphate (2-5 mM), and DL-myo-inositol-1-PO4 (1-2 mM). D-myo-Inositol-1,3,4-(PO4)3 (1 mM) and L-myo-inositol-1-PO4 (2 mM) were intermediate in their ability to release the cell surface HSPG, whereas heparin (2 mg/ml), yeast phosphomannan (4 mg/ml), D-xylose-1-PO4 (50 mM), D-glucose-6-SO4 (50 mM), and myo-inositol hexasulfate (5 mM) were ineffective. When 35SO2/4- was added to cell cultures, the total cell surface HSPG increased linearly, but the percentage of the total cell surface [35SO4]HSPG that was released by myo-inositol-PO4 increased with time during the labeling period, reaching a maximum of 65% after 5 h. When cells were labeled for 12 h without insulin in the medium, the maximum amount of cell surface HSPG that was released by myo-inositol-PO4 was reduced to 30%. However, when cells labeled in the absence of insulin were treated with phosphatidylinositol-specific phospholipase C and then myo-inositol-PO4, the release of the cell surface [35SO4]HSPG was increased to 73%. When the [35SO4]HSPG that was released from the cell surface by treatment with myo-inositol-PO4 was added to cultures of unlabeled hepatocytes, it was taken up very rapidly and a portion of the internalized HSPG was converted to free heparan SO4 chains which appeared in the nucleus. Uptake was Ca2+- and Mg2+-independent. The amount of [35SO4]HSPG taken up was markedly reduced when the myo-inositol-PO4-releasable [35SO4]HSPG was pretreated with trypsin, thermolysin, alkaline borohydride, or alkaline phosphatase. When the cells were grown in inositol-deficient medium or in the presence of myo-inositol-PO4, the amount of heparan SO4 found in the nucleus was markedly reduced, and the cells no longer exhibited contact inhibition. These effects of myo-inositol deficiency on the growth and nuclear heparan SO4 were accentuated by addition of LiCl to the cultures to prevent phosphatidylinositol synthesis from the endogenous myo-inositol-PO4.(ABSTRACT TRUNCATED AT 400 WORDS)
将大鼠肝细胞系培养于含胎牛血清和胰岛素的日高氏培养基中,并用35SO2/4-进行标记。用多种配体处理细胞,以从细胞周围基质中置换出硫酸乙酰肝素蛋白聚糖(HSPG)。用D-甘露糖-6-磷酸(50 mM)、D-葡萄糖-6-磷酸(50 mM)、肌醇-2-磷酸(2 - 5 mM)、肌醇六磷酸(2 - 5 mM)和DL-肌醇-1-磷酸(1 - 2 mM)可获得最大释放量。D-肌醇-1,3,4-(磷酸)3(1 mM)和L-肌醇-1-磷酸(2 mM)释放细胞表面HSPG的能力处于中等水平,而肝素(2 mg/ml)、酵母磷酸甘露聚糖(4 mg/ml)、D-木糖-1-磷酸(50 mM)、D-葡萄糖-6-硫酸(50 mM)和肌醇六硫酸(5 mM)则无效。当向细胞培养物中添加35SO2/4-时,细胞表面总HSPG呈线性增加,但在标记期间,肌醇磷酸释放的细胞表面[35SO4]HSPG的百分比随时间增加,5小时后达到最大值65%。当细胞在培养基中无胰岛素的情况下标记12小时时,肌醇磷酸释放的细胞表面HSPG的最大量降至30%。然而,当用磷脂酰肌醇特异性磷脂酶C处理无胰岛素标记的细胞,然后用肌醇磷酸处理时,细胞表面[35SO4]HSPG的释放增加到73%。当用肌醇磷酸处理从细胞表面释放的[35SO4]HSPG添加到未标记的肝细胞培养物中时,它被迅速摄取,并且一部分内化的HSPG转化为游离的硫酸乙酰肝素链,出现在细胞核中。摄取不依赖于Ca2+和Mg2+。当肌醇磷酸可释放的[35SO4]HSPG用胰蛋白酶、嗜热菌蛋白酶、碱性硼氢化钠或碱性磷酸酶预处理时,摄取的[35SO4]HSPG量明显减少。当细胞在缺乏肌醇的培养基中生长或在肌醇磷酸存在下生长时,细胞核中发现的硫酸乙酰肝素量明显减少,并且细胞不再表现出接触抑制。通过向培养物中添加LiCl以防止从内源性肌醇磷酸合成磷脂酰肌醇,可加剧肌醇缺乏对生长和细胞核硫酸乙酰肝素的这些影响。(摘要截短至400字)